Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12

Cancer Immunol Immunother. 2023 Aug;72(8):2783-2797. doi: 10.1007/s00262-023-03459-7. Epub 2023 May 11.

Abstract

There is strong evidence that chemotherapy can induce tumor necrosis which can be exploited for the targeted delivery of immuno-oncology agents into the tumor microenvironment (TME). We hypothesized that docetaxel, a chemotherapeutic agent that induces necrosis, in combination with the bifunctional molecule NHS-IL-12 (M9241), which delivers recombinant IL-12 through specific targeting of necrotic regions in the tumor, would provide a significant antitumor benefit in the poorly inflamed murine tumor model, EMT6 (breast), and in the moderately immune-infiltrated tumor model, MC38 (colorectal). Docetaxel, as monotherapy or in combination with NHS-IL-12, promoted tumor necrosis, leading to the improved accumulation and retention of NHS-IL-12 in the TME. Significant antitumor activity and prolonged survival were observed in cohorts receiving docetaxel and NHS-IL-12 combination therapy in both the MC38 and EMT6 murine models. The therapeutic effects were associated with increased tumor infiltrating lymphocytes and were dependent on CD8+ T cells. Transcriptomics of the TME of mice receiving the combination therapy revealed the upregulation of genes involving crosstalk between innate and adaptive immunity factors, as well as the downregulation of signatures of myeloid cells. In addition, docetaxel and NHS-IL-12 combination therapy effectively controlled tumor growth of PD-L1 wild-type and PD-L1 knockout MC38 in vivo, implying this combination could be applied in immune checkpoint refractory tumors, and/or tumors regardless of PD-L1 status. The data presented herein provide the rationale for the design of clinical studies employing this combination or similar combinations of agents.

Keywords: Combination immunotherapy; Docetaxel; Immunotherapy; NHS-IL-12; Necrosis; rIL-12.

MeSH terms

  • Animals
  • B7-H1 Antigen*
  • CD8-Positive T-Lymphocytes
  • Cell Line, Tumor
  • Docetaxel
  • Immunotherapy
  • Interleukin-12 / pharmacology
  • Mice
  • Necrosis
  • Neoplasms*
  • Tumor Microenvironment

Substances

  • Docetaxel
  • B7-H1 Antigen
  • Interleukin-12